A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer

Takuo Shibayama, Katsuyuki Hotta, Nagio Takigawa, Atsuhiko Tada, Hiroshi Ueoka, Shingo Harita, Katsuyuki Kiura, Masahiro Tabata, Yoshihiko Segawa, Naoyuki Nogami, Shoichi Kuyama, Tetsu Shinkai, Mitsune Tanimoto

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Cisplatin-based chemotherapy is considered to be a standard treatment in patients with relapsed or extensive-disease (ED) small-cell lung cancer (SCLC), the survival benefit remains modest. Relapsed or ED-SCLC patients were enrolled. Topotecan and amrubicin were administered on Days 1-5 and on Days 3-5, respectively. Nine patients received a total of 24 cycles. Since all three patients experienced dose-limiting toxicity (grade 4 neutropenia lasting for more than 4 days, grade 3 febrile neutropenia, and grade 4 thrombocytopenia) at the third dose level (topotecan: 0.75 mg/m2, amrubicin 40 mg/m2), the maximum tolerated dose was determined to be this dose level. Objective response was observed in six patients (67%). The maximum concentration (Cmax) and area under the plasma concentration-time curve (AUC) of amrubicin increased in a dose-dependent manner. Amrubicin did not influence the pharmacokinetics of topotecan. The Cmax and AUC of amrubicin were correlated with the duration of grade 4 neutropenia. The mean Cmax of topotecan on day 2 in responders (22.9 ± 3.6) was significantly higher than that in non-responders (10.9 ± 0.4). This phase I study showed the safety and activity of two-drug combination of amrubicin and topotecan in patients with relapsed or ED-SCLC.

Original languageEnglish
Pages (from-to)189-195
Number of pages7
JournalLung Cancer
Volume53
Issue number2
DOIs
Publication statusPublished - Aug 2006

Fingerprint

Topotecan
Small Cell Lung Carcinoma
Pharmacology
Neutropenia
Area Under Curve
Febrile Neutropenia
Maximum Tolerated Dose
Drug Combinations
Cisplatin
amrubicin
Pharmacokinetics
Safety
Drug Therapy
Survival

Keywords

  • Amrubicin
  • Lung cancer
  • Pharmacokinetics
  • Phase I trial
  • Topotecan

ASJC Scopus subject areas

  • Oncology

Cite this

A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer. / Shibayama, Takuo; Hotta, Katsuyuki; Takigawa, Nagio; Tada, Atsuhiko; Ueoka, Hiroshi; Harita, Shingo; Kiura, Katsuyuki; Tabata, Masahiro; Segawa, Yoshihiko; Nogami, Naoyuki; Kuyama, Shoichi; Shinkai, Tetsu; Tanimoto, Mitsune.

In: Lung Cancer, Vol. 53, No. 2, 08.2006, p. 189-195.

Research output: Contribution to journalArticle

Shibayama, Takuo ; Hotta, Katsuyuki ; Takigawa, Nagio ; Tada, Atsuhiko ; Ueoka, Hiroshi ; Harita, Shingo ; Kiura, Katsuyuki ; Tabata, Masahiro ; Segawa, Yoshihiko ; Nogami, Naoyuki ; Kuyama, Shoichi ; Shinkai, Tetsu ; Tanimoto, Mitsune. / A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer. In: Lung Cancer. 2006 ; Vol. 53, No. 2. pp. 189-195.
@article{8a4255b68b3247e8a943eedadad07ca6,
title = "A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer",
abstract = "Cisplatin-based chemotherapy is considered to be a standard treatment in patients with relapsed or extensive-disease (ED) small-cell lung cancer (SCLC), the survival benefit remains modest. Relapsed or ED-SCLC patients were enrolled. Topotecan and amrubicin were administered on Days 1-5 and on Days 3-5, respectively. Nine patients received a total of 24 cycles. Since all three patients experienced dose-limiting toxicity (grade 4 neutropenia lasting for more than 4 days, grade 3 febrile neutropenia, and grade 4 thrombocytopenia) at the third dose level (topotecan: 0.75 mg/m2, amrubicin 40 mg/m2), the maximum tolerated dose was determined to be this dose level. Objective response was observed in six patients (67{\%}). The maximum concentration (Cmax) and area under the plasma concentration-time curve (AUC) of amrubicin increased in a dose-dependent manner. Amrubicin did not influence the pharmacokinetics of topotecan. The Cmax and AUC of amrubicin were correlated with the duration of grade 4 neutropenia. The mean Cmax of topotecan on day 2 in responders (22.9 ± 3.6) was significantly higher than that in non-responders (10.9 ± 0.4). This phase I study showed the safety and activity of two-drug combination of amrubicin and topotecan in patients with relapsed or ED-SCLC.",
keywords = "Amrubicin, Lung cancer, Pharmacokinetics, Phase I trial, Topotecan",
author = "Takuo Shibayama and Katsuyuki Hotta and Nagio Takigawa and Atsuhiko Tada and Hiroshi Ueoka and Shingo Harita and Katsuyuki Kiura and Masahiro Tabata and Yoshihiko Segawa and Naoyuki Nogami and Shoichi Kuyama and Tetsu Shinkai and Mitsune Tanimoto",
year = "2006",
month = "8",
doi = "10.1016/j.lungcan.2006.05.008",
language = "English",
volume = "53",
pages = "189--195",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer

AU - Shibayama, Takuo

AU - Hotta, Katsuyuki

AU - Takigawa, Nagio

AU - Tada, Atsuhiko

AU - Ueoka, Hiroshi

AU - Harita, Shingo

AU - Kiura, Katsuyuki

AU - Tabata, Masahiro

AU - Segawa, Yoshihiko

AU - Nogami, Naoyuki

AU - Kuyama, Shoichi

AU - Shinkai, Tetsu

AU - Tanimoto, Mitsune

PY - 2006/8

Y1 - 2006/8

N2 - Cisplatin-based chemotherapy is considered to be a standard treatment in patients with relapsed or extensive-disease (ED) small-cell lung cancer (SCLC), the survival benefit remains modest. Relapsed or ED-SCLC patients were enrolled. Topotecan and amrubicin were administered on Days 1-5 and on Days 3-5, respectively. Nine patients received a total of 24 cycles. Since all three patients experienced dose-limiting toxicity (grade 4 neutropenia lasting for more than 4 days, grade 3 febrile neutropenia, and grade 4 thrombocytopenia) at the third dose level (topotecan: 0.75 mg/m2, amrubicin 40 mg/m2), the maximum tolerated dose was determined to be this dose level. Objective response was observed in six patients (67%). The maximum concentration (Cmax) and area under the plasma concentration-time curve (AUC) of amrubicin increased in a dose-dependent manner. Amrubicin did not influence the pharmacokinetics of topotecan. The Cmax and AUC of amrubicin were correlated with the duration of grade 4 neutropenia. The mean Cmax of topotecan on day 2 in responders (22.9 ± 3.6) was significantly higher than that in non-responders (10.9 ± 0.4). This phase I study showed the safety and activity of two-drug combination of amrubicin and topotecan in patients with relapsed or ED-SCLC.

AB - Cisplatin-based chemotherapy is considered to be a standard treatment in patients with relapsed or extensive-disease (ED) small-cell lung cancer (SCLC), the survival benefit remains modest. Relapsed or ED-SCLC patients were enrolled. Topotecan and amrubicin were administered on Days 1-5 and on Days 3-5, respectively. Nine patients received a total of 24 cycles. Since all three patients experienced dose-limiting toxicity (grade 4 neutropenia lasting for more than 4 days, grade 3 febrile neutropenia, and grade 4 thrombocytopenia) at the third dose level (topotecan: 0.75 mg/m2, amrubicin 40 mg/m2), the maximum tolerated dose was determined to be this dose level. Objective response was observed in six patients (67%). The maximum concentration (Cmax) and area under the plasma concentration-time curve (AUC) of amrubicin increased in a dose-dependent manner. Amrubicin did not influence the pharmacokinetics of topotecan. The Cmax and AUC of amrubicin were correlated with the duration of grade 4 neutropenia. The mean Cmax of topotecan on day 2 in responders (22.9 ± 3.6) was significantly higher than that in non-responders (10.9 ± 0.4). This phase I study showed the safety and activity of two-drug combination of amrubicin and topotecan in patients with relapsed or ED-SCLC.

KW - Amrubicin

KW - Lung cancer

KW - Pharmacokinetics

KW - Phase I trial

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=33745594550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745594550&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2006.05.008

DO - 10.1016/j.lungcan.2006.05.008

M3 - Article

C2 - 16806573

AN - SCOPUS:33745594550

VL - 53

SP - 189

EP - 195

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -